"Combination Prevention" Gains Ground as High Priority
HIV/AIDS Clinical Care Meeting Report
Subscription Required
The idea of packaging proven prevention strategies took hold at this year’s International AIDS Conference.
The Latest Studies in Treatment-Naive Patients
HIV/AIDS Clinical Care Meeting Report
Subscription Required
Trials described at the 2008 International AIDS Conference highlighted possible new options for initial therapy but also raised questions about abacavir/3TC as an NRTI backbone.
Is Abacavir Therapy Associated with Increased Risk for MI?
HIV/AIDS Clinical Care Meeting Report
Subscription Required
Despite a wealth of data presented at the 2008 International AIDS Conference, the answer remains a qualified "maybe."
Virologic Failure with Abacavir — ACTG 5202 and the GSK Response
HIV/AIDS Clinical Care Meeting Report
Free Article
This year’s International AIDS Conference delivered conflicting information about the virologic efficacy of abacavir/3TC.
Negative Study of Pregabalin for HIV-Associated Peripheral Neuropathy
HIV/AIDS Clinical Care Meeting Report
Subscription Required
In a randomized trial described at the 2008 International AIDS Conference, pain scores declined to the same extent with pregabalin as with placebo.
Tenofovir and Renal Toxicity
HIV/AIDS Clinical Care Meeting Report
Subscription Required
Tenofovir generally has a favorable toxicity profile, but close monitoring might be needed in certain subgroups, according to data presented at the 2008 International AIDS Conference.
Report from the XVII International AIDS Conference
HIV/AIDS Clinical Care Meeting Report
Free Article
The ACC editors share their perspectives on the most important clinical findings presented at the meeting.
Report from the XVII International HIV Drug Resistance Workshop
HIV/AIDS Clinical Care Meeting Report
Free Article
An expert’s take on the most clinically relevant findings from this year’s resistance meeting
By Daniel R. Kuritzkes, MD
July 14, 2008
Durability of New Agents for Treatment-Experienced Patients
HIV/AIDS Clinical Care Meeting Report
Subscription Required
Etravirine, raltegravir, and maraviroc have all continued to show excellent virologic control at 48 weeks; vicriviroc data are also encouraging.
Opportunistic Infections: TB, HIV, and XDR TB
HIV/AIDS Clinical Care Meeting Report
Free Article
Data presented at the 15th Retrovirus Conference highlighted the importance of strengthening airborne infection-control practice and relying less on hospital TB care, particularly in resource-limited settings.
